- Condition: Hepatitis C Virus
Interventions: Biological: Peginterferon Lambda-1a; Biological: Peginterferon Alfa-2a; Drug: Ribavirin; Drug: Telaprevir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified May 2012 - Condition: Hepatitis B
Interventions: Drug: Entecavir; Drug: Peginterferon alfa-2a
Sponsors: Sun Yat-sen University; Sun Yat-sen University
Not yet recruiting - verified May 2012 - Condition: Chronic Viral Hepatitis B Without Delta-agent
Interventions: Drug: Telbivudine; Drug: Entecavir
Sponsors: Asan Medical Center; Asan Medical Center
Not yet recruiting - verified May 2012 - Condition: Chronic Hepatitis B
Interventions: Drug: Group A (Zeffix, Sebivo, Hepsera); Drug: Group B (Baraclude, Viread)
Sponsors: Yonsei University; Yonsei University; Bristol-Myers Squibb; Asan Medical Center; Seoul St. Mary's Hospital; Soonchunhyang University Hospital; Pusan National University Hospital; Kyungpook National University; Hallym University Medical Center; Chonbuk National University Hospital
Not yet recruiting - verified May 2012 - Condition: Chronic Hepatitis B
Intervention: Drug: Entecavir + Tenofovir (MDR group)
Sponsors: Yonsei University; Yonsei University; Bristol-Myers Squibb; Asan Medical Center; Seoul St. Mary's Hospital
Not yet recruiting - verified May 2012 - Condition: Hepatitis C
Interventions: Drug: MK-2748; Drug: Placebo
Sponsors: Merck; Merck
Not yet recruiting - verified May 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: boceprevir; Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin (Copegus]; Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin (Copegus]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2012 - Condition: Chronic Hepatitis B
Intervention: Drug: Pegalyted interferon, Entecavir
Sponsors: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh; Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Recruiting - verified May 2012 - Condition: Chronic Hepatitis C
Interventions: Drug: Boceprevir; Drug: Peginterferon alpha-2b; Drug: Ribavirin; Drug: Boceprevir; Drug: Peginterferon alfa-2b; Drug: Ribavirin
Sponsors: Schering-Plough; Schering-Plough
Not yet recruiting - verified May 2012 - Condition: Hepatitis b Vaccine
Intervention:
Sponsors: Medical Corps, Israel Defense Force; Medical Corps, Israel Defense Force
Recruiting - verified May 2012 - Condition: Hepatic Impairment
Intervention: Drug: telaprevir
Sponsors: Janssen Infectious Diseases BVBA; Janssen Infectious Diseases BVBA
Not yet recruiting - verified May 2012 - Conditions: Hepatitis B; HBV
Interventions: Drug: Single Ascending Dose (SAD) Cohorts GS-9620; Drug: Multiple Ascending Dose (MAD) Cohorts
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified December 2011 - Condition: Hepatitis B
Interventions: Drug: Single Ascending Dose (SAD) Cohorts GS-9620; Drug: Multiple Ascending Dose (MAD) Cohorts GS-9620
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified December 2011 - Condition: Chronic Liver Disease
Intervention: Drug: Perfusion MRI (adofosveset trisodium, Ablavar, Lantheus)
Sponsors: Mount Sinai School of Medicine; Bachir Taouli
Recruiting - verified May 2012 - Conditions: Hepatitis C; Liver Transplant Recipient
Interventions: Drug: Peginterferon alfa-2a; Drug: Ribavirin; Drug: telaprevir
Sponsors: University of Chicago; University of Chicago
Recruiting - verified May 2012 - Condition: Chronic Hepatitis B
Interventions: Drug: Telbivudine; Drug: Tenofovir; Drug: Entecavir
Sponsors: Pusan National University Yangsan Hospital; Pusan National University Yangsan Hospital
Recruiting - verified April 2012 - Conditions: Hepatitis C Virus; Liver Transplant Recipient; Recurrent Fibrosis
Interventions: Drug: Rifaximin; Drug: Placebo
Sponsors: Columbia University; Columbia University
Recruiting - verified May 2012 - Condition: Hepatitis C, Chronic
Interventions: Biological: Pegasys; Biological: P1101, 48 doses; Biological: P1101, 24 doses; Biological: P1101, 12 doses
Sponsors: PharmaEssentia; PharmaEssentia
Recruiting - verified April 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: ribavirin [Copegus]; Drug: peginterferon alfa-2a [Pegasys]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Chronic Hepatitis C Infection
Interventions: Drug: Panel 1: JNJ-47910382; Drug: Panel 1: Placebo; Drug: Panel 2: JNJ-47910382; Drug: Panel 2: Placebo; Drug: Panel 3: JNJ-47910382; Drug: Panel 3: Placebo; Drug: Panel 4: JNJ-47910382; Drug: Panel 4: Placebo
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Not yet recruiting - verified April 2012 - Conditions: Chronic Hepatitis B e Antigen Positive; Chronic Hepatitis B e Antigen Negative
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 2012 - Condition: Hepatitis C
Interventions: Drug: TMC647055; Drug: TMC647055; Drug: TVR; Drug: TVR; Drug: TVR; Drug: PegFN; Drug: RBV
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2012 - Condition: Hepatitis C
Intervention:
Sponsors: Johnson & Johnson Medical, China; Johnson & Johnson Medical, China
Recruiting - verified May 2012 - Condition: Hepatitis C Virus
Interventions: Drug: Asunaprevir (ASV); Drug: Daclatasvir (DCV); Drug: PBO matching ASV; Drug: Placebo (PBO) matching DCV; Drug: Pegylated-interferon alfa 2a (PegIFN); Drug: Ribavirin (RBV)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified April 2012 - Condition: Hepatitis C
Intervention: Drug: Boceprevir
Sponsors: University of Calgary; University of Calgary; Merck
Not yet recruiting - verified April 2012 - Condition: Chronic Hepatitis C Virus
Interventions: Drug: VX-222; Drug: telaprevir; Drug: ribavirin
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Not yet recruiting - verified April 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: RO5024048; Drug: RO5024048; Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin [Copegus]; Drug: danoprevir; Drug: ritonavir
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2012 - Condition: Chronic Hepatitis C Infection
Interventions: Drug: Valacyclovir; Drug: Placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Chronic Hepatitis C
Intervention:
Sponsors: Association HGE CHU Bordeaux Sud; Association HGE CHU Bordeaux Sud
Recruiting - verified March 2012 - Condition: Hepatitis C
Interventions: Drug: BI 201335 high dose; Drug: BI 201335 high dose; Drug: BI 201335 high dose; Drug: BI201335 low dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Hepatitis C
Interventions: Drug: BI 201335; Drug: BI 201335
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Hepatitis C Virus
Interventions: Drug: Asunaprevir; Drug: Daclatasvir; Drug: Peg-interferon Alfa-2a; Drug: Ribavirin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified April 2012 - Condition: Hepatitis C Virus Infection, Response to Therapy of
Intervention: Behavioral: Personalized Physical Activity and Psycho-Education (PPAPE) Program
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital; National Health Research Institutes, Taiwan
Recruiting - verified April 2012 - Conditions: Malignancy; Hepatitis B
Interventions: Drug: Entecavir; Drug: Lamivudine
Sponsors: Seoul National University Hospital; Seoul National University Hospital
Not yet recruiting - verified April 2012 - Condition: Hepatitis C
Intervention:
Sponsors: Peking University People's Hospital; Peking University People's Hospital; Bristol-Myers Squibb
Recruiting - verified May 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: BI 201335; Drug: Ethinylestradiol; Drug: Ethinylestradiol; Drug: levonorgestrel; Drug: levonorgestrel
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Vitamin A Deficiency
Interventions: Dietary Supplement: retinyl palmitate; Dietary Supplement: Placebo
Sponsors: USDA, Western Human Nutrition Research Center; USDA, Western Human Nutrition Research Center; International Centre for Diarrhoeal Disease Research, Bangladesh; World Health Organization
Recruiting - verified April 2012 - Conditions: Hepatitis C; HIV
Interventions: Drug: PSI-7977; Drug: Efavirenz; Drug: Tenofovir; Drug: Emtricitabine; Drug: Atazanavir plus Ritonavir; Drug: Zidovudine; Drug: Lamivudine
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: Hepatitis C
Interventions: Drug: Single Ascending Dose Cohorts GS-9620; Drug: Multiple Ascending Dose Cohorts GS-9620
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified December 2011 - Condition: Vaccination; Complications, Reaction, Serum
Intervention: Biological: hepatitis B vaccine
Sponsors: Centers for Disease Control and Prevention, China; Wu Jiang; Beijing Municipal Science & Technology Commission
Recruiting - verified March 2012 - Condition: Hepatitis B
Intervention: Other: Renal Safety Surveillance
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: MK-8325; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: ALS-002158; Drug: Placebo
Sponsors: Alios Biopharma Inc.; Alios Biopharma Inc.; Vertex Pharmaceuticals Incorporated
Recruiting - verified March 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: ALS-002200; Drug: Placebo
Sponsors: Alios Biopharma Inc.; Alios Biopharma Inc.; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2012 - Condition: Chronic Hepatitis B
Intervention: Drug: Switching from adefovir (10mg/day) to tenofovir (300mg/day)
Sponsors: Yonsei University; Yonsei University
Recruiting - verified May 2012 - Condition: Chronic Hepatitis B Virus Treatment
Intervention:
Sponsors: Ain Shams University; Ain Shams University
Recruiting - verified March 2012 - Conditions: Hepatitis C; Hepatocellular Carcinoma
Intervention: Drug: GS-7977+RBV
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Condition: Hepatitis C
Intervention: Drug: Sitagliptin
Sponsors: Institut National de la Santé Et de la Recherche Médicale, France; Institut National de la Santé Et de la Recherche Médicale, France
Not yet recruiting - verified March 2012 - Conditions: Hepatitis C; Hypertension
Interventions: Drug: Amlodipine; Drug: Diltiazem
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Merck
Not yet recruiting - verified March 2012 - Condition: Hepatitis C, Chronic
Interventions: Biological: peginterferon alfa-2a; Drug: ribavirin; Drug: boceprevir
Sponsors: Schering-Plough; Schering-Plough
Not yet recruiting - verified May 2012 - Condition: Chronic Hepatitis C
Intervention:
Sponsors: French National Agency for Research on AIDS and Viral Hepatitis; French National Agency for Research on AIDS and Viral Hepatitis
Recruiting - verified March 2012 - Condition: Hepatitis
Intervention: Drug: MK-5172
Sponsors: Merck; Merck
Not yet recruiting - verified April 2012 - Condition: Chronic Hepatitis C
Interventions: Drug: Ypeginterferon alfa-2b; Drug: Pegasys; Drug: Ypeginterferon alfa-2b; Drug: Pegasys
Sponsors: Xiamen Amoytop Biotech Co., Ltd.; Xiamen Amoytop Biotech Co., Ltd.
Recruiting - verified April 2012 - Conditions: Hepatitis B; Chronic Hepatitis B e Antigen Positive
Intervention: Drug: Entecavir/Peginterferon
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 2012 - Condition: Hepatitis C Infection
Intervention: Drug: ITX 5061
Sponsors: Schiano, Thomas D., MD; Schiano, Thomas D., MD; iTherX Pharma, Inc.
Not yet recruiting - verified March 2012 - Condition: Hepatitis C
Intervention:
Sponsors: Institut National de la Santé Et de la Recherche Médicale, France; Institut National de la Santé Et de la Recherche Médicale, France
Recruiting - verified February 2012 - Condition: Chronic Hepatitis B
Intervention: Drug: Nucleos(t)ide analogue treatment and add-on of peginterferon for 24 weeks
Sponsors: Foundation for Liver Research; Foundation for Liver Research
Not yet recruiting - verified April 2012 - Condition: Hepatitis C Infection
Interventions: Biological: MBL-HCV1; Drug: Telaprevir
Sponsors: MassBiologics; MassBiologics
Not yet recruiting - verified April 2012 - Safety, Pharmacokinetics and Pharmacodynamics of MK-8742 in Hepatitis C Infected Males (MK-8742-002)Condition: Hepatitis, Viral, Human
Interventions: Drug: MK-8742; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Conditions: Hepatitis C, Chronic; Non-Alcoholic Fatty Liver Disease
Intervention: Device: Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)
Sponsors: HepQuant, LLC; HepQuant, LLC
Recruiting - verified April 2012 - Condition: Inflammatory Bowel Disease
Interventions: Biological: ENGERIX-B (HBV Vaccine); Biological: Sci-B-Vac
Sponsors: Soroka University Medical Center; Soroka University Medical Center
Not yet recruiting - verified April 2012 - Condition: Chronic Hepatitis B
Intervention:
Sponsors: Yonsei University; Yonsei University
Recruiting - verified May 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207127 NA; Drug: BI 207127 NA; Drug: BI 201335 NA; Drug: BI 201335 NA; Drug: peginterferon; Drug: peginterferon
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Hepatitis C Chronic
Intervention:
Sponsors: Schering-Plough; Schering-Plough
Not yet recruiting - verified April 2012 - Condition: Chronic Hepatitis C
Interventions: Drug: Peg-Interferon; Procedure: Liver Samples from FNA; Procedure: Liver Samples from CNB; Procedure: Blood Samples; Drug: Ribavarin; Drug: 800 mg MK-5172; Drug: 100 mg MK-5172; Procedure: Liver samples from CNB and FNA
Sponsors: Merck; Merck
Not yet recruiting - verified March 2012 - Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected PatientsCondition: Hepatitis C, Chronic
Interventions: Drug: tenofovir; Drug: ribavirin; Drug: ribavirin; Drug: ribavirin; Drug: caffeine; Drug: caffeine; Drug: midazolam; Drug: midazolam; Drug: tolbutamide; Drug: tolbutamide; Drug: pegylated inteferon; Drug: pegylated interferon; Drug: BI 201335; Drug: BI 201335; Drug: BI 201335; Drug: BI 207127; Drug: BI 207127; Drug: BI 207127
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Other Condition That May be a Focus of Clinical Attention
Intervention: Biological: Vaccination against hepatitis A
Sponsors: Federal University of São Paulo; Federal University of São Paulo; Fundação de Amparo à Pesquisa do Estado de São Paulo; AFIP: Associação Fundo de Incentivo à Pesquisa
Not yet recruiting - verified February 2012 - Condition: Chronic Hepatitis B
Intervention: Drug: pegylated Interferon-alpha 2a
Sponsors: Yonsei University; Yonsei University
Recruiting - verified February 2012 - Condition: Chronic Hepatitis B
Intervention: Drug: Pegylated interferon alfa-2a plus nucleos(t)ide(s)
Sponsors: Johannes Gutenberg University Mainz; Johannes Gutenberg University Mainz; Roche Pharma AG
Not yet recruiting - verified April 2012 - Condition: Chronic Hepatitis C
Interventions: Drug: BMS-929075; Drug: BMS-929075; Drug: BMS-929075; Drug: BMS-929075; Drug: Placebo matching BMS-929075; Drug: Placebo matching BMS-929075
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified January 2012 - Condition: Chronic Hepatitis C Infection
Interventions: Drug: Valacyclovir; Drug: Placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; GlaxoSmithKline
Recruiting - verified January 2012 - Condition: Chronic Hepatitis B
Interventions: Drug: tenofovir disoproxil fumarate 300mg per day; Drug: Placebo
Sponsors: E-DA Hospital; E-DA Hospital; Gilead Sciences; Taipei Institute of Pathology, Taiwan
Recruiting - verified May 2012 - Condition: Hepatitis B, Chronic
Intervention: Drug: Telbivudine, Adefovir dipivoxil
Sponsors: Third Affiliated Hospital, Sun Yat-Sen University; Third Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial People's Hospital; Guangzhou 8th People's Hospital
Recruiting - verified January 2012 - Condition: Hepatitis C
Intervention: Drug: TMC435
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: Hepatitis C Virus Recurrence
Interventions: Drug: Silibinin (Legalon-SIL); Drug: Saline
Sponsors: Rottapharm; Rottapharm; Azienda Ospedaliera Universitaria Policlinico
Recruiting - verified January 2012 - Conditions: Hepatitis C; HCV
Intervention:
Sponsors: University of Cincinnati; University of Cincinnati; Merck
Recruiting - verified January 2012 - Condition: Chronic Hepatitis C
Intervention:
Sponsors: French National Agency for Research on AIDS and Viral Hepatitis; French National Agency for Research on AIDS and Viral Hepatitis
Recruiting - verified January 2012 - Conditions: Genotype 1 Chronic Hepatitis C; Treatment naïve With HCV-1/HIV-1 Coinfection; Treatment Experienced With HCV-1/HIV-1 Coinfection
Interventions: Drug: Telaprevir; Drug: Pegylated Interferon alfa-2a; Drug: Ribavirin
Sponsors: Tibotec BVBA; Tibotec BVBA
Not yet recruiting - verified January 2012 - Condition: Hepatitis B Virus Recurrence
Intervention: Drug: Hepabulin IV
Sponsors: SK Chemicals Co.,Ltd.; SK Chemicals Co.,Ltd.
Recruiting - verified December 2011 - Condition: Chronic Hepatitis C Virus
Interventions: Drug: VX-222; Drug: telaprevir; Drug: ribavirin; Biological: peginterferon-alfa-2a
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified January 2012 - Condition: HCV Infection
Interventions: Drug: ABT-267; Drug: ABT-450/r; Drug: ABT-333; Drug: Ribavirin (RBV)
Sponsors: Abbott; Abbott
Recruiting - verified May 2012 - Condition: Hepatitis C
Intervention: Drug: BMS-914143
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Hepatitis C
Interventions: Drug: Telaprevir + peginterferon alfa + ribavirin; Drug: peginterferon alfa + ribavirin; Drug: peginterferon alfa + ribavirin
Sponsors: Janssen-Cilag International NV; Janssen-Cilag International NV
Available - verified April 2012 - Conditions: Chronic Hepatitis C; Liver Cirrhosis
Intervention: Drug: keyhole-limpet hemocyanin
Sponsors: Medical University of Graz; Medical University of Graz
Recruiting - verified January 2012 - Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified February 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: IDX719 or matching placebo (oral suspension); Drug: IDX719 or matching placebo (oral suspension)
Sponsors: Idenix Pharmaceuticals; Idenix Pharmaceuticals
Recruiting - verified January 2012 - Condition: Chronic Hepatitis C
Interventions: Drug: telaprevir formulation A; Drug: telaprevir Formulation B; Drug: telaprevir Formulation C; Drug: telaprevir Formulation D
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified March 2012 - Conditions: Hepatitis B; Renal Failure With Tubular Necrosis
Intervention: Biological: plasma and urine samples, sample with ADN
Sponsors: University Hospital, Limoges; University Hospital, Limoges
Recruiting - verified December 2011 - Condition: Hepatitis C, Chronic
Interventions: Drug: Telaprevir; Drug: Telaprevir
Sponsors: Janssen-Cilag International NV; Janssen-Cilag International NV
Recruiting - verified April 2012 - Condition: Hepatitis D
Intervention: Drug: Lonafarnib
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified December 2011 - Conditions: Treatment of Genotype 1 Chronic HCV; Liver Transplantation
Interventions: Drug: Telaprevir; Drug: Pegylated interferon alfa-2a; Drug: Ribavirin
Sponsors: Janssen-Cilag International NV; Janssen-Cilag International NV
Recruiting - verified April 2012 - Condition: Liver Fibrosis
Intervention: Device: Fibroscan® of Echosens, Aixplorer® of Supersonic Imagine, Aplio XG of Toshiba, QRS software developed by Pr I.Bricault, Acuson S2000 of Siemens
Sponsors: University Hospital, Grenoble; University Hospital, Grenoble; Clinical investigation center, Technological innovation
Recruiting - verified April 2012 - Condition: Hepatitis C
Interventions: Drug: BMS-790052 (Daclatasvir); Drug: Telaprevir; Drug: Peginterferon alfa-2a; Drug: Ribavirin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Conditions: Depression; Hepatitis c
Intervention:
Sponsors: Centro Hospitalar Lisboa Norte; Centro Hospitalar Lisboa Norte
Not yet recruiting - verified December 2011 - Condition: Alcoholic Liver Disease
Intervention: Drug: LACTOWELL
Sponsors: Chuncheon Sacred Heart Hospital; Chuncheon Sacred Heart Hospital
Recruiting - verified December 2011 - Condition: Hepatitis B, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: peginterferon alfa-2a [Pegasys]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2012 - Condition: Hepatitis C
Interventions: Drug: BMS-790052 (Daclatasvir); Drug: BMS-650032 (Asunaprevir)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified January 2012 - Conditions: Hepatitis B Infection; Chronic Infection; Viremia
Interventions: Drug: TDF for mothers, HBIG + HBV vaccine for infants; Other: HBIG and HBV vaccine for infants
Sponsors: New Discovery LLC; New Discovery LLC; Gilead Sciences
Recruiting - verified March 2012 - Condition: Hepatitis C
Intervention: Drug: Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: danoprevir; Drug: ritonavir; Drug: RO5024048; Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: Hepatitis C
Interventions: Drug: PSI-352938; Drug: PSI-7977
Sponsors: Pharmasset; Pharmasset
Recruiting - verified December 2011 - Condition: Hepatitis C, Chronic
Interventions: Drug: mericitabine; Drug: Placebo; Drug: boceprevir; Drug: boceprevir; Drug: boceprevir; Drug: Placebo; Drug: Pegasys; Drug: Copegus; Drug: Pegasys; Drug: Copegus
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: mericitabine; Drug: mericitabine; Drug: Placebo; Drug: Placebo; Drug: Pegasys; Drug: Copegus; Drug: Pegasys; Drug: Copegus; Drug: telaprevir
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Conditions: HIV Infections; Hepatitis C
Interventions: Drug: Pegylated-Interferon Alfa 2b (PEG-IFN); Drug: Ribavirin (RBV); Drug: Boceprevir (BOC)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Condition: Hepatitis C
Interventions: Drug: TMC435; Drug: TVR
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: Chronic Hepatitis B
Interventions: Drug: GSK548470 300 mg tablet; Drug: ETV 0.5 mg capsule
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Hepatitis B, Chronic
Intervention: Drug: GSK548470 300 mg tablet
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Hepatitis C
Intervention:
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; University of Florida
Recruiting - verified November 2011 - Conditions: Bacterial Infections; Virus Diseases
Interventions: Biological: V419; Biological: Rotavirus vaccine; Biological: Prevenar 13; Biological: INFANRIX hexa
Sponsors: Sanofi Pasteur MSD; Sanofi Pasteur MSD; Merck
Recruiting - verified May 2012 - Condition: Acute Alcoholic Hepatitis
Interventions: Biological: ELAD (Extracorporeal Liver Assist System); Biological: Standard of care only
Sponsors: Vital Therapies, Inc.; Vital Therapies, Inc.
Not yet recruiting - verified November 2011 - Condition: Hepatitis C, Genotype 1
Interventions: Drug: BMS-790052 (Daclatasvir); Drug: Ribavirin; Drug: Peg-Interferon alfa 2a
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Condition: Hepatitis C
Intervention: Drug: Sildenafil and Boceprevir
Sponsors: Imperial College London; Imperial College London
Not yet recruiting - verified December 2011 - Condition: Hepatitis C
Interventions: Drug: Telaprevir; Drug: Ribavirin; Biological: peginterferon alfa-2a
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2012 - Condition: Hepatitis C
Interventions: Drug: Telaprevir; Drug: ribavirin; Drug: peginterferon alfa-2a
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified April 2012 - Condition: Hepatitis C
Interventions: Drug: Telaprevir; Drug: ribavirin; Biological: peginterferon alfa-2a; Drug: ribavirin; Biological: peginterferon alfa-2a; Drug: ribavirin; Biological: peginterferon alfa-2a
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2012 - Condition: Hepatitis C Infection
Intervention: Drug: Boceprevir
Sponsors: Arrowhead Regional Medical Center; Arrowhead Regional Medical Center
Recruiting - verified November 2011 - Condition: Chronic Hepatitis C
Interventions: Drug: MP-424 (generic name:Telaprevir); Drug: Ribavirin; Drug: Peginterferon alfa-2b
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Recruiting - verified November 2011 - Condition: Chronic Hepatitis C
Interventions: Drug: MP-424 (generic name:Telaprevir); Drug: Ribavirin; Drug: Peginterferon alfa-2b
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Recruiting - verified November 2011 - Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft RecipientsConditions: Renal Allograft; Hepatitis C
Interventions: Drug: Everolimus; Drug: Cyclosporine; Drug: Tacrolimus
Sponsors: Irmandade Santa Casa de Misericórdia de Porto Alegre; Irmandade Santa Casa de Misericórdia de Porto Alegre; NOVARTIS BIOCIÊNCIAS S.A.
Recruiting - verified January 2012 - Condition: Chronic Hepatitis B
Intervention: Drug: Pegylated interferon alfa-2a
Sponsors: Beijing Ditan Hospital; Beijing Ditan Hospital
Recruiting - verified November 2011 - Condition: Depression
Interventions: Drug: Mirtazapine; Other: Supportive psychotherapy
Sponsors: Seoul National University Boramae Hospital; Seoul National University Boramae Hospital
Recruiting - verified October 2011 - Condition: Hepatitis B
Intervention:
Sponsors: Public Health Service of Amsterdam; Public Health Service of Amsterdam; UMC Utrecht
Recruiting - verified November 2011 - Condition: Chronic Hepatitis B
Interventions: Drug: Tenofovir disoproxil fumarate; Drug: Lamivudine plus adefovir
Sponsors: Taipei Veterans General Hospital,Taiwan; Taipei Veterans General Hospital,Taiwan
Not yet recruiting - verified December 2011 - Condition: Hepatitis C, Chronic
Interventions: Drug: telaprevir; Drug: Peginterferon alfa-2a; Drug: ribavirin
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2012 - Condition: Chronic Hepatitis C
Interventions: Drug: anti-CD3 monoclonal antibody; Drug: Sodium Chloride placebo
Sponsors: Inspira Medical AB; Inspira Medical AB; NasVax Ltd
Not yet recruiting - verified October 2011 - Conditions: Hepatitis; Tuberculosis
Intervention:
Sponsors: All India Institute of Medical Sciences, New Delhi; All India Institute of Medical Sciences, New Delhi
Recruiting - verified February 2012 - Condition: Chronic Hepatitis C
Interventions: Drug: BMS-650032; Drug: BMS-650032; Drug: BMS-790052; Drug: BMS-790052; Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified November 2011 - Condition: Hepatitis B, Chronic
Interventions: Drug: Peginterferon alfa-2a; Drug: Entecavir
Sponsors: Gangnam Severance Hospital; Gangnam Severance Hospital; Roche Pharma AG
Not yet recruiting - verified October 2011 - Condition: Chronic Hepatitis C
Intervention:
Sponsors: Inje University; Inje University
Recruiting - verified October 2011 - Condition: Hepatitis C
Interventions: Drug: Armodafinil; Drug: Placebo
Sponsors: Research Foundation for Mental Hygiene; Research Foundation for Mental Hygiene; Mount Sinai School of Medicine; Weill Medical College of Cornell University
Recruiting - verified November 2011 - Condition: Hepatitis B
Intervention: Biological: Twinrix
Sponsors: University of Aarhus; University of Aarhus; Aarhus University Hospital; Monash Medical Centre
Not yet recruiting - verified October 2011 - Conditions: Chronic Hepatitis C; Menopause
Intervention: Drug: Pegylated Interferon, Ribavirin, Boceprevir
Sponsors: University of Modena and Reggio Emilia; University of Modena and Reggio Emilia; Merck
Not yet recruiting - verified October 2011 - Condition: Chronic Hepatitis C Infection
Interventions: Drug: Valacyclovir; Drug: Placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; GlaxoSmithKline
Recruiting - verified March 2012 - Conditions: Poliomyelitis; Haemophilus Influenzae Type b Disease; Hepatitis B; Diphtheria; Pertussis; Tetanus
Interventions: Biological: Combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus and Haemophilus influenzae type b vaccine (GSK217744) - Formulation A; Biological: Combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus and Haemophilus influenzae type b vaccine (GSK217744) - Formulation B; Biological: Infanrix hexaTM; Biological: Pfizer's 13-valent pneumococcal polysaccharide conjugate vaccine (Prevenar 13®)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012 - Condition: Hepatitis C
Interventions: Drug: BMS-790052 (NS5A Replication Complex Inhibitor); Drug: Placebo matching BMS-790052; Drug: Pegylated-interferon alfa 2a; Drug: Pegylated-interferon alfa 2a; Drug: Ribavirin; Drug: Ribavirin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011 - Condition: Hepatitis C, Chronic
Interventions: Drug: PPI-668; Drug: Placebo
Sponsors: Presidio Pharmaceuticals, Inc.; Presidio Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Condition: Healthy
Interventions: Drug: TG-2349; Drug: placebo
Sponsors: TaiGen Biotechnology Co., Ltd.; TaiGen Biotechnology Co., Ltd.
Recruiting - verified January 2012 - Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified January 2012 - Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified January 2012 - Condition: Vaccine Response Impaired
Interventions: Biological: hepatitis A vaccine; Biological: hepatitis A vaccine
Sponsors: Sormland County Council, Sweden; Sormland County Council, Sweden
Recruiting - verified October 2011 - Conditions: Hepatitis; HIV/AIDS
Interventions: Drug: Boceprevir; Drug: Peg-Interferon-alfa 2B; Drug: Ribavirin
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2011 - Condition: Sino-implant (II)
Intervention: Drug: Sino-implant (II)
Sponsors: FHI 360; FHI 360; Bill and Melinda Gates Foundation
Recruiting - verified May 2012 - Condition: Contraception
Intervention:
Sponsors: FHI 360; FHI 360; United States Agency for International Development (USAID)
Not yet recruiting - verified October 2011 - Conditions: HIV Infection; Hepatitis C
Intervention: Behavioral: Contigent voucher incentive (CVI)
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Drug Abuse (NIDA)
Recruiting - verified October 2011 - Conditions: Hepatitis C; Medication Adherence
Interventions: Other: enhanced DOT (both pegylated interferon alfa-2a and ribavirin); Other: standard DOT (PEG-DOT control arm)
Sponsors: Albert Einstein College of Medicine of Yeshiva University; Albert Einstein College of Medicine of Yeshiva University; National Institute on Drug Abuse (NIDA)
Recruiting - verified September 2011 - Condition: Hepatitis C
Interventions: Drug: 200 mg INX-08189 Fasted; Drug: Placebo QD Fasted; Drug: 100 mg INX-08189 QD with ribavirin; Drug: Placebo QD with ribavirin; Drug: 100 mg INX-08189 with low-fat meal; Drug: Placebo with low-fat meal; Drug: 100 mg INX-08189 BID Fasted; Drug: Placebo BID Fasted
Sponsors: Inhibitex; Inhibitex
Recruiting - verified November 2011 - Condition: Renal Insufficiency
Intervention: Drug: ATeGe-Fresenius
Sponsors: Hospital Vall d'Hebron; Hospital Vall d'Hebron; Hospital Universitari Vall d'Hebron Research Institute
Recruiting - verified January 2012 - Condition: Hepatitis B
Intervention:
Sponsors: Beijing Municipal Science & Technology Commission; Beijing Municipal Science & Technology Commission
Recruiting - verified September 2011 - Condition: Chronic Hepatitis C
Interventions: Drug: Peginterferon alfa2a; Drug: Ribavirin; Drug: Peginterferon alfa2a; Drug: Ribavirin
Sponsors: Third Affiliated Hospital, Sun Yat-Sen University; Third Affiliated Hospital, Sun Yat-Sen University
Recruiting - verified May 2012 - Condition: Hepatitis C Virus
Interventions: Drug: ABT-450/r; Drug: ABT-267; Drug: ribavirin
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Condition: Chronic Hepatitis B
Interventions: Biological: HBV DNA vaccine; Other: Placebo
Sponsors: The 458 Hospital of Chinese PLA; Fuqiang Yang
Recruiting - verified September 2011 - Conditions: Human Immunodeficiency Virus Infection; Hepatitis C
Intervention:
Sponsors: G & W Laboratories Inc.; G & W Laboratories Inc.; Alquest; SMART Biotech Ltd
Recruiting - verified October 2011 - Condition: Hepatitis B, Chronic
Interventions: Drug: telbivudine (ROADMAP); Drug: Telbivudine (Standard of Care)
Sponsors: Nanfang Hospital of Southern Medical University; Nanfang Hospital of Southern Medical University; Major Science and Technology Special Project of China Eleventh Five-year; Novartis
Recruiting - verified March 2012 - Condition: HIV
Intervention: Biological: Sci-B-Vac
Sponsors: Tel-Aviv Sourasky Medical Center; Tel-Aviv Sourasky Medical Center; SciGen, Israel, the vaccine manufacturer, will be providing 300 Sci-B-Vac doses
Not yet recruiting - verified October 2011 - Condition: Chronic Hepatitis C
Intervention: Dietary Supplement: Vit D
Sponsors: Hanyang University; Hanyang University; Roche Pharma AG
Not yet recruiting - verified September 2011 - Condition: Hepatitis C
Interventions: Biological: AdCh3NSmut1; Other: Placebo; Biological: MVA-NSmut
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Condition: Chronic Hepatitis C
Intervention: Dietary Supplement: Quercetin
Sponsors: University of California, Los Angeles; University of California, Los Angeles; American Association for Cancer Research; Tower Cancer Research Foundation; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified September 2011 - Condition: Chronic Hepatitis B
Interventions: Drug: Adefovir Dipivoxil and polyene phosphatidylcholine; Drug: Adefovir Dipivoxil
Sponsors: Capital Medical University; Jun Cheng; Sanofi-Aventis; Fujian Cosunter Pharmaceutical Co. Ltd
Not yet recruiting - verified September 2011 - Condition: Chronic Hepatitis C
Interventions: Drug: 48-weeks course; Drug: Ribavirin; Drug: Peginterferon alfa2a; Drug: Ribavirin
Sponsors: Third Affiliated Hospital, Sun Yat-Sen University; Third Affiliated Hospital, Sun Yat-Sen University
Recruiting - verified September 2011 - Condition: Hepatitis C, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin [Copegus]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: Hepatitis C
Intervention: Biological: implantation
Sponsors: Medgenics Medical Israel Ltd.; Medgenics Medical Israel Ltd.
Not yet recruiting - verified May 2011 - Condition: Hepatitis C
Intervention: Biological: Subcutan implantation of autologus skin graft after ex-vivo treatment
Sponsors: Medgenics Medical Israel Ltd.; Medgenics Medical Israel Ltd.
Not yet recruiting - verified September 2011 - Condition: Hepatitis C
Intervention: Genetic: Interleukin 28B genotype
Sponsors: Henry Ford Health System; Henry Ford Health System
Recruiting - verified September 2011 - Condition: Hepatitis C Virus
Interventions: Drug: BMS-790052 (HCV NS5A Replication Co-factor Inhibitor); Drug: BMS-650032 (HCV NS3 Protease Inhibitor); Drug: Peginterferon alfa-2a; Drug: Ribavirin; Drug: Ribavirin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Hepatitis C
Intervention:
Sponsors: Closter Pharma; Closter Pharma
Not yet recruiting - verified August 2011 - Condition: Hepatitis C, Chronic
Intervention: Drug: Boceprevir
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified April 2012 - Conditions: Hepatitis C; HIV
Intervention: Drug: boceprevir; etravirine
Sponsors: University of Colorado, Denver; University of Colorado, Denver
Recruiting - verified August 2011 - Conditions: HIV Infection; Hepatitis C
Intervention:
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Drug Abuse (NIDA)
Recruiting - verified August 2011 - Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Conditions: Chronic Hepatitis; Chronic Hepatitis C; Chronic Alcoholic Hepatitis
Intervention: Drug: High dose vitamin C
Sponsors: Seoul National University Hospital; Seoul National University Hospital
Not yet recruiting - verified August 2011 - Condition: Hepatitis C Virus
Intervention: Drug: rimantadine
Sponsors: The Leeds Teaching Hospitals NHS Trust; The Leeds Teaching Hospitals NHS Trust; Cancer Research UK
Not yet recruiting - verified July 2011 - Condition: Hepatitis C
Interventions: Drug: Peginterferon alfa-2a; Drug: Ribavirin; Drug: telaprevir
Sponsors: University of Vermont; University of Vermont
Recruiting - verified January 2012 - Conditions: Hepatitis C; Renal Cell Carcinoma; Colorectal Cancer
Intervention: Other: Hepatitis C testing
Sponsors: Henry Ford Health System; Henry Ford Health System; Schering-Plough
Recruiting - verified June 2011 - Conditions: Liver Diseases, Alcoholic; Alcoholism; HIV; Hepatitis C
Interventions: Other: Integrated Stepped Care (ISC); Other: Treatment as Usual
Sponsors: Yale University; Yale University; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Department of Veterans Affairs
Not yet recruiting - verified August 2011 - Condition: Chronic Hepatitis C
Intervention: Drug: Boceprevir
Sponsors: Azienda Ospedaliero-Universitaria di Parma; Azienda Ospedaliero-Universitaria di Parma
Not yet recruiting - verified July 2011 - Conditions: Chronic Hepatitis C; Genotype 1
Interventions: Procedure: Educational Intervention; Other: No Intervention
Sponsors: Chronic Liver Disease Foundation; Chronic Liver Disease Foundation; Clinical Development Group
Recruiting - verified February 2012 - Conditions: Cancer; Liver Cancer; Hepatocellular Carcinoma
Interventions: Drug: PI-88; Other: Placebo
Sponsors: Medigen Biotechnology Corporation; Medigen Biotechnology Corporation
Recruiting - verified February 2012 - Condition: Chronic Hepatitis B
Intervention:
Sponsors: Foundation for Liver Research; Foundation for Liver Research
Recruiting - verified May 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: BI201335; Drug: BI201335 24W; Drug: PegIFN/RBV; Drug: PegIFN/RBV
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: GSK2336805; Drug: Pegylated interferon alfa-2a; Drug: Ribavirin; Drug: GSK2336805 Matching Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Pharmaceutical Product Development Clinical Research Organization (CRO)
Recruiting - verified February 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: Boceprevir (BOC); Drug: Placebo to boceprevir; Drug: Peginterferon alfa-2b (PEG); Drug: Ribavirin (RBV); Drug: Cross-Over Boceprevir Treatment
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified April 2012 - Condition: Hepatitis C
Intervention: Drug: MK-5172
Sponsors: Merck; Merck
Recruiting - verified March 2012 - Condition: Hepatitis C
Interventions: Drug: BMS-790052 (NS5A Replication Complex Inhibitor); Drug: Peg-Interferon Alfa-2a; Drug: Ribavirin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011 - Conditions: Drug Use; HIV; Hepatitis C
Intervention: Behavioral: Brief motivational intervention
Sponsors: Rhode Island Hospital; Rhode Island Hospital; National Institute on Drug Abuse (NIDA)
Recruiting - verified July 2011 - Conditions: Underlying Liver Disease; Hepatitis; Fibrosis of Liver; Cirrhosis With Suspicion of Liver Cancer; Lesion on a Prior Ultrasound, CT or Outside MRI
Intervention:
Sponsors: University of Nebraska; University of Nebraska
Recruiting - verified August 2011 - Conditions: Hepatitis; Tuberculosis, Pulmonary
Intervention: Drug: isoniazid, rifampin, pyrazinamide
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital
Recruiting - verified July 2011 - Conditions: Liver Cirrhosis; Chronic Hepatitis B
Intervention: Drug: telbivudine
Sponsors: The Fifth People's Hospital of Suzhou; The Fifth People's Hospital of Suzhou
Recruiting - verified June 2011 - Condition: Chronic Hepatitis
Intervention: Drug: Peginterferon alpha-2a + Ribavirin
Sponsors: Casa Sollievo della Sofferenza IRCCS; Casa Sollievo della Sofferenza IRCCS; Casa di Cura Mater Dei; IRCCS L. Spallanzani; Ospedale Francesco Ferrari, Casarano; Ospedale SS. Annunziata, Sassari; IRCCS Policlinico S. Matteo; Arcispedale S. Anna, Ferrara; Azienda Ospedaliero-Universitaria, Catania; Ospedale di Venosa; Ospedale R. Dimiccoli, Barletta; IRCCS De Bellis, Castellana; USL Napoli 1; Ospedale San Giuseppe Moscati, Avellino; Cardarelli Hospital; Ospedale Civile Vittorio Emanuele II, Bisceglie; Azienda Ospedaliero-Universitaria Careggi; Azienda Ospedaliera V. Cervello; Ospedale Civile Spirito Santo; Ospedale di Canosa di Puglia; University of Palermo; San Camillo Hospital, Rome; Campus Bio-Medico University; Ospedale Sandro Pertini, Roma; Ospedali Riuniti, Foggia; Ospedale SS. Annunziata, Taranto; Ospedale di Mottola; Ospedale Santa Caterina Novella, Galatina; University of Florence; Ospedale Valduce, Como; University of Bari; Azienda Ospedaliera, Siracusa; Azienda Ospedaliera, Lucca
Recruiting - verified April 2012 - Condition: Chronic Hepatitis C
Interventions: Drug: GS-5885, GS-9451, PEG , RBV; Drug: PEG, RBV
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified February 2012 - Condition: Chronic Hepatitis
Interventions: Drug: oral antiviral for HBV; Drug: tenofovir disoproxil fumarate
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Chronic Hepatitis C
Intervention: Drug: statin
Sponsors: Bader, Ted, M.D.; Bader, Ted, M.D.
Not yet recruiting - verified June 2011 - Conditions: Sustained Virologic Response; IL28B Polymorphism
Interventions: Drug: peginterferon alfa 2a (pegasys); Drug: peginterferon alfa-2a (pegasys)
Sponsors: The Catholic University of Korea; The Catholic University of Korea; Ulsan University Hospital; NHIC Ilsan hospital; Inje University; Soonchunhyang University Hospital; Yonsei University; Chungnam National University; Keimyung University; Kyungpook National University; Konyang University Hospital; Inha University Hospital; Hallym University Medical Center
Recruiting - verified October 2008 - Condition: Chronic Hepatitis B
Interventions: Drug: Peginterferon alfa-2a; Drug: Nucleos(t)ide analogue
Sponsors: Foundation for Liver Research; Foundation for Liver Research; Hoffmann-La Roche
Not yet recruiting - verified February 2012 - Condition: Chronic Hepatitis B
Interventions: Drug: HBsAg and HBcAg combination; Drug: Peginterferon alfa-2b
Sponsors: Clinical Research Organization, Dhaka, Bangladesh; Clinical Research Organization, Dhaka, Bangladesh
Recruiting - verified June 2011 - Condition: Acute on Chronic Hepatic Failure
Interventions: Drug: Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO); Drug: Placebo
Sponsors: Institute of Liver and Biliary Sciences, India; Institute of Liver and Biliary Sciences, India
Recruiting - verified October 2011 - Condition: Hepatitis C, Chronic
Interventions: Drug: IDX184; Drug: IDX184
Sponsors: Idenix Pharmaceuticals; Idenix Pharmaceuticals
Recruiting - verified February 2012 - Condition: Hepatitis B
Intervention: Drug: Entecavir and peginterferon
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Pittsburgh
Not yet recruiting - verified May 2012 - Condition: Hepatitis B
Interventions: Drug: Tenofovir; Drug: Combination of peginterferon alfa 2a and tenofovir
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Pittsburgh
Not yet recruiting - verified February 2012 - Condition: Hepatitis B
Interventions: Other: Control Arm; Drug: Entecavir and peginterferon
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified January 2012 - Condition: Hepatitis C, Chronic, Healthy Volunteer
Interventions: Drug: RO5428029; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Conditions: Decompensated Cirrhosis; Bleeding Varices
Interventions: Procedure: Transjugular intrahepatic portosystemic shunt; Drug: Non-selective beta blocker + Endoscopic treatment
Sponsors: Fourth Military Medical University; Fourth Military Medical University
Recruiting - verified May 2011 - Condition: Hepatitis C, Chronic
Interventions: Drug: Pegylated interferon alfa 2b; Drug: Ribavirin
Sponsors: Kirby Institute; Kirby Institute; Merck
Not yet recruiting - verified May 2011 - Conditions: Cytomegalovirus Infection; Hepatitis C
Intervention:
Sponsors: Sociedad Española de Trasplante Hepático; Sociedad Española de Trasplante Hepático; Roche Farma, S.A.
Recruiting - verified November 2011 - Condition: Chronic Hepatitis C
Interventions: Drug: PSI-7977; Drug: BMS-790052; Drug: Ribavirin; Drug: Ribavirin; Drug: Ribavirin; Drug: BMS-790052; Drug: PSI-7977
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Pharmasset
Recruiting - verified January 2012 - Condition: Thrombocytopenia
Intervention: Drug: E5501 (previously known as AKR-501 monomaleate)
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified November 2011 - Conditions: Diphtheria; Hepatitis B; Haemophilus Influenzae Type b Disease; Poliomyelitis; Pertussis; Tetanus
Intervention: Biological: Infanrix hexa™
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified April 2012 - Conditions: Hepatitis; HIV; Liver Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC); Washington DC Veterans Affairs Medical Center
Recruiting - verified February 2012 - Condition: Hepatitis B
Interventions: Biological: HepavaxGene (thiomersal free); Biological: Engerix B
Sponsors: Crucell Holland BV; Crucell Holland BV
Recruiting - verified March 2012 - Conditions: Plasmodium Falciparum Malaria; Hepatitis B
Interventions: Biological: GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049; Biological: Engerix-B vaccine; Biological: Infanrix/Hib vaccine; Biological: Polio Sabin vaccine; Biological: Rotarix vaccine; Biological: Synflorix vaccine; Biological: Measles vaccine; Biological: Yellow fever vaccine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified November 2011 - Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified July 2011 - Condition: Hepatitis C
Intervention: Other: Blood samples
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Conditions: Liver Failure; Hepatitis B
Intervention: Drug: 5 days dexamethasone therapy
Sponsors: Third Military Medical University; Third Military Medical University
Recruiting - verified June 2011 - Conditions: Hepatitis B, Chronic; Liver Fibrosis
Intervention: Drug: Treatment with entecavir(Baraclude®)
Sponsors: RWTH Aachen University; RWTH Aachen University; Hannover Medical School; Hannover Clinical Trial Center GmbH
Not yet recruiting - verified March 2012 - Condition: Acute Hepatitis C
Interventions: Drug: Peginterferon alfa-2a; Drug: Ribavirin
Sponsors: Kirby Institute; Kirby Institute
Not yet recruiting - verified April 2011 - Condition: Chronic Hepatitis C
Interventions: Drug: ChronVac-C + SOC; Drug: SOC
Sponsors: ChronTech Pharma AB; ChronTech Pharma AB; Inovio Pharmaceuticals
Recruiting - verified October 2011 - Conditions: HIV; Hepatitis C; HIV and Hepatitis C Coinfection
Intervention:
Sponsors: University of Cincinnati; University of Cincinnati; Merck
Recruiting - verified January 2012 - Condition: Hepatitis C
Interventions: Drug: PegIFN/RBV; Drug: BI 201335
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Chronic Hepatitis B
Interventions: Drug: Therapeutic HBV vaccine, entecavir; Drug: Empty liposome, entecavir
Sponsors: Chongqing Jiachen Biotechnology Ltd.; Chongqing Jiachen Biotechnology Ltd.; Third Military Medical University
Recruiting - verified September 2011 - Condition: Contraceptive Usage
Intervention:
Sponsors: FHI 360; FHI 360; United States Agency for International Development (USAID)
Recruiting - verified August 2011 - Condition: Hepatitis C
Intervention: Drug: TMC435
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Conditions: HIV Coinfection; Hepatitis C; Hepatitis B; Hepatotoxicity
Interventions: Drug: Maraviroc; Drug: Placebo
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Conditions: HIV; Hepatitis C; Hepatitis B; Syphilis
Interventions: Device: Rapid tests for HIV, HCV, HBV, and syphilis; Device: HIV/HCV; Device: HIV/syphilis; Device: HIV only
Sponsors: California State University, Long Beach; California State University, Long Beach; National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2012 - Conditions: HIV; Hepatitis C; Syphilis; Herpes Simplex Type II
Interventions: Behavioral: MMT provider dosage training; Behavioral: targeted counseling; Other: national guidelines
Sponsors: Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; National Center for AIDS/STD Control and Prevention, China CDC
Recruiting - verified April 2012 - Condition: Chronic Hepatitis B
Intervention: Drug: Stopping TDF therapy
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified November 2011 - Condition: Hepatitis C
Interventions: Biological: Pegylated Interferon Lambda (pegIFNλ); Drug: BMS-790052 (NS5A Inhibitor); Drug: Ribavirin (RBV); Drug: BMS-650032 (NS3 Protease Inhibitor); Biological: Pegylated Interferon Alfa-2a (pegIFNα-2a); Biological: Pegylated Interferon Lambda (pegIFNλ); Drug: Ribavirin (RBV); Biological: Pegylated Interferon Lambda (pegIFNλ); Drug: Ribavirin (RBV); Drug: BMS-790052 (NS5A Inhibitor); Drug: BMS-650032 (NS3 Protease Inhibitor); Drug: Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor); Drug: Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor); Drug: Placebo for Ribavirin (RBV); Drug: Placebo for Ribavirin (RBV)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Conditions: Chronic Hepatitis B e Antigen Positive; Chronic Hepatitis B e Antigen Negative
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 2012 - Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC TherapyCondition: Hepatitis B
Interventions: Drug: Entecavir; Drug: Entecavir, Adefovir; Drug: Entecavir, Adefovir
Sponsors: Nanfang Hospital of Southern Medical University; Nanfang Hospital of Southern Medical University; JiangSu Chia-Tai Tianqin Pharmacy Co.Ltd
Recruiting - verified March 2012 - Condition: Hepatitis C Infection
Interventions: Biological: MVA-NSmut; Biological: AdCh3NSmut; MVA-NSmut; Biological: AdCh3NSmut; MVA-NSmut; Biological: AdCh3NSmut ; MVA-NSmut; Biological: AdCh3NSmut; MVA-NSmut
Sponsors: Okairos; Okairos; University of Oxford; Oxford University Hospitals NHS Trust; University Hospital Birmingham
Recruiting - verified October 2011 - Condition: Healthy, no Evidence of Disease
Interventions: Biological: hepatitis B antigen peptide; Other: placebo; Other: immunoenzyme technique
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Cancer Institute (NCI)
Not yet recruiting - verified January 2012 - Condition: Contraception
Intervention: Drug: one of 5 products
Sponsors: FHI 360; FHI 360; National Institutes of Health (NIH)
Recruiting - verified April 2012 - Conditions: HIV Infection; Hepatitis C
Interventions: Drug: Anti-HIV Agents; Drug: raltegravir; Drug: Emtricitabine and tenofovir disoproxil fumarate
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Drug Abuse (NIDA)
Recruiting - verified August 2011 - Condition: Hepatitis B Virus Infection, Pregnancy
Intervention: Drug: antiviral therapy
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital
Recruiting - verified August 2011 - Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: Chronic Hepatitis B
Interventions: Drug: Tenofovir Disoproxil Fumarate, Peginterferon α-2a; Drug: Tenofovir Disoproxil Fumarate, Peginterferon α-2a; Drug: Tenofovir Disoproxil Fumarate; Drug: Peginterferon α-2a
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: Chronic Hepatitis C
Intervention:
Sponsors: Avera McKennan Hospital & University Health Center; Avera McKennan Hospital & University Health Center
Recruiting - verified January 2011 - Condition: Hepatitis C
Interventions: Drug: TMC435; Drug: Placebo
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2012 - Condition: Hepatitis C
Interventions: Drug: Placebo; Drug: TMC435
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: Hepatitis C
Interventions: Drug: Placebo; Drug: TMC435
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: Hepatitis C Virus
Intervention: Drug: Insulin
Sponsors: McGill University Health Center; McGill University Health Center
Recruiting - verified August 2011 - Condition: Chronic Hepatitis B
Intervention: Drug: telbivudine
Sponsors: Yonsei University; Yonsei University
Recruiting - verified January 2012 - Condition: Liver Fibrosis
Intervention:
Sponsors: China Medical University Hospital; China Medical University Hospital
Recruiting - verified June 2011 - Condition: Hepatitis B
Intervention:
Sponsors: University of Pittsburgh; University of Pittsburgh; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified June 2011 - Condition: Hepatitis B
Intervention:
Sponsors: University of Pittsburgh; University of Pittsburgh; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified July 2011 - Condition: Chronic Hepatitis B
Interventions: Drug: Tenofovir; Drug: Telbivudine; Drug: Tenofovir plus Telbivudine
Sponsors: Institute of Liver and Biliary Sciences, India; Institute of Liver and Biliary Sciences, India
Recruiting - verified June 2011 - Condition: Chronic Hepatitis C Infection
Interventions: Drug: PSI-7977 in combination with RBV; Drug: PSI-7977 in combination with RBV and PEG-IFN; Drug: PSI-7977 in combination with RBV and PEG-IFN; Drug: PSI-7977 in combination with RBV and PEG-IFN; Drug: PSI-7977 monotherapy; Drug: PSI-7977 in combination with RBV and PEG-IFN; Drug: PSI-7977 in combination with RBV; Drug: PSI-7977 in combination with RBV; Drug: PSI-7977 in combination with RBV; Drug: PSI-7977 in combination with RBV; Drug: PSI-7977 in combination with 800 mg RBV; Drug: PSI-7977 in combination with GS-5885 and RBV; Drug: PSI-7977 in combination with RBV
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified February 2012 - Condition: Hepatitis C
Interventions: Drug: Silymarin; Drug: Placebo
Sponsors: Bukwang Pharmaceutical; Bukwang Pharmaceutical
Recruiting - verified October 2011 - Condition: Hepatitis C Infection
Interventions: Drug: Placebo; Drug: SCY-635; Drug: SCY-635; Drug: SCY-635; Drug: peginterferon alfa 2a; Drug: Ribavirin
Sponsors: Scynexis Incorporated; Scynexis Incorporated
Recruiting - verified June 2011 - Conditions: Hearing Loss; Sudden Deafness
Intervention:
Sponsors: Carmel Medical Center; Carmel Medical Center
Not yet recruiting - verified December 2010 - Condition: Chronic Hepatitis B
Intervention: Drug: PEG-IFN and entecavir
Sponsors: Chulalongkorn University; Chulalongkorn University
Recruiting - verified June 2011 - Conditions: Hepatocellular Carcinoma; Liver Cancer
Intervention: Drug: bavituximab and sorafenib
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Recruiting - verified October 2010 - Condition: Alcoholic Hepatitis
Intervention:
Sponsors: University of Aarhus; University of Aarhus
Recruiting - verified March 2012 - Conditions: HIV; Hepatitis C; Liver Fibrosis
Interventions: Drug: Raltegravir; Drug: Ritonavir-boosted protease inhibitor
Sponsors: McGill University Health Center; McGill University Health Center; Merck; Canadian HIV Trials Network
Recruiting - verified March 2012 - Condition: Hepatitis B, Chronic
Interventions: Drug: Entecavir and Pegylated interferon α-2a Sequential Treatment Group; Drug: Pegylated interferon α-2a Monotreatment Group
Sponsors: Hanyang University; Hanyang University; Roche Pharma AG
Recruiting - verified June 2011 - Conditions: Chronic HIV Infection; HCV Coinfection
Intervention: Drug: Fosamprenavir
Sponsors: Fundacion SEIMC-GESIDA; Fundacion SEIMC-GESIDA; ViiV Healthcare
Recruiting - verified June 2011 - Condition: Hepatitis C
Intervention: Drug: Interferon Alfa-2b
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; Tibotec Pharmaceutical Limited
Recruiting - verified February 2012 - Condition: Lymphoma
Intervention: Drug: nucleoside analog reverse transcriptase inhibitor
Sponsors: Fudan University; Fudan University
Recruiting - verified September 2010 - Conditions: Human Immunodeficiency Virus (HIV); Hepatitis C, Chronic
Intervention:
Sponsors: George Washington University; George Washington University
Recruiting - verified September 2010 - Condition: Hepatitis B Virus
Interventions: Drug: pegIFN; Drug: pegIFNα-2a
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Chronic Hepatitis B
Intervention: Device: 13C Methacetin Breath Test (BreathID)
Sponsors: Hadassah Medical Organization; Hadassah Medical Organization
Recruiting - verified June 2011 - Condition: Hepatitis B
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2012 - Conditions: Hepatitis C; HIV
Intervention: Drug: Pegylated interferon with ribavirin
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID); Fundacion de Investigacion de Diego
Recruiting - verified April 2012 - Condition: Hepatitis C
Interventions: Drug: Placebo; Drug: Nitazoxanide
Sponsors: National Liver Institute, Egypt; National Liver Institute, Egypt
Recruiting - verified September 2011 - Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified September 2011 - Conditions: Hepatitis C Infection; Thrombocytopenia
Interventions: Biological: romiplostim; Drug: ribavirin; Other: placebo; Biological: PEG-interferon alfa-2a; Other: laboratory biomarker analysis
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center
Recruiting - verified May 2012 - Condition: Hepatitis A
Intervention:
Sponsors: Rijnstate Hospital; Rijnstate Hospital
Recruiting - verified June 2011 - Conditions: Hepatitis C; Depression
Intervention: Other: Depression collaborative care model
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified December 2011 - Conditions: HIV Infections; Hepatitis; Sexually Transmitted Infections
Interventions: Behavioral: Traditional Prevention; Behavioral: Web-based Prevention
Sponsors: National Development and Research Institutes, Inc.; National Development and Research Institutes, Inc.; National Institute on Drug Abuse (NIDA)
Recruiting - verified July 2011 - Condition: Hepatorenal Syndrome Type 1
Interventions: Drug: Terlipressin; Drug: Placebo
Sponsors: Ikaria Holdings Inc.; Ikaria Holdings Inc.
Recruiting - verified May 2012 - Condition: Recurrent Hepatitis C After Liver Transplantation
Intervention: Drug: mycophenolate to sirolimus switch
Sponsors: London Health Sciences Centre; London Health Sciences Centre
Recruiting - verified June 2011 - Conditions: Hepatitis B; Liver Transplantation
Intervention: Drug: Hepatitis B immune globulin
Sponsors: Grifols Biologicals Inc.; Instituto Grifols, S.A.
Recruiting - verified January 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: BI 207127; Drug: BI 207127; Drug: BI 201335; Drug: BI 201335; Drug: BI 201335; Drug: BI 201335; Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207127; Drug: Ribavirin; Drug: BI 207127; Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207127; Drug: BI 207127; Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207127; Drug: BI 201335; Drug: BI 201335; Drug: BI 201335; Drug: BI 207217; Drug: BI 201335; Drug: BI 201335; Drug: BI 201335; Drug: BI 207127; Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207127
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: HIV Infections; Hepatitis C
Interventions: Drug: Raltegravir; Drug: Atazanavir/Ritonavir
Sponsors: St. James's Hospital; St. James's Hospital
Recruiting - verified March 2010 - Condition: Chronic Hepatitis C - Genotype 3
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified February 2010 - Conditions: Immunologic Tests; Hepatitis B Infection
Intervention: Other: Blood withdrawal
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified June 2011 - Condition: Hepatitis C Virus
Intervention: Drug: ribavirin
Sponsors: University of Colorado, Denver; University of Colorado, Denver; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified July 2011 - Conditions: HIV; Hepatitis B
Interventions: Drug: Tenofovir/lamivudine/lopinavir-ritonavir; Drug: Zidovudine/lamivudine/lopinavir-ritonavir
Sponsors: Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; National Center for AIDS/STD Control and Prevention, China CDC
Not yet recruiting - verified October 2011 - Condition: Hepatitis C
Interventions: Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut ; Ad6NSmut; Biological: AdCh3NSmut; Ad6NSmut
Sponsors: Okairos; Okairos; University of Oxford
Recruiting - verified October 2011 - Condition: Hepatitis B, Chronic
Intervention:
Sponsors: Johann Wolfgang Goethe University Hospitals; Johann Wolfgang Goethe University Hospitals
Recruiting - verified May 2012 - Condition: Kidney-transplant Recipients With Chronic Hepatitis E Virus Infection
Interventions: Other: blood samples; Other: blood samples
Sponsors: Assistance Publique Hopitaux De Marseille; Assistance Publique Hopitaux De Marseille
Recruiting - verified April 2012 - Conditions: Liver Fibrosis; Liver Cirrhosis; Viral Hepatitis; Liver Tumour; Cardiac Failure; Biliary Cholestasis.
Interventions: Device: ARFI measurement; Device: ARFI measurement; Device: ARFI measurement
Sponsors: University Hospital, Bordeaux; University Hospital, Bordeaux
Recruiting - verified December 2011 - Condition: Chronic Hepatitis B Virus, Pediatric
Interventions: Drug: Entecavir; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Conditions: Cervical Neoplasia; HPV Infections
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Primary Sclerosing Cholangitis
Intervention: Drug: ursodeoxycholic acid (UDCA) withdrawal and reinstitution
Sponsors: University of Tennessee; University of Tennessee; Mount Sinai School of Medicine; Children's Memorial Hospital; University of Colorado, Denver; University of California, San Francisco; University of Pittsburgh; Children's Hospital Medical Center, Cincinnati; Phoenix Children's Hospital
Recruiting - verified February 2012 - Conditions: Hepatitis; Cytokines; Pregnancy
Intervention:
Sponsors: Maulana Azad Medical College; Maulana Azad Medical College; Indian Council of Medical Research
Recruiting - verified July 2011 - Conditions: Chronic Renal Failure; Humoral Immune Alterations
Interventions: Procedure: High flux polymethylmetacrylate membrane; Procedure: Polysulfone membrane; Biological: Hepatitis B serological control; Biological: Seric sCD40 level
Sponsors: University Hospital, Bordeaux; University Hospital, Bordeaux
Recruiting - verified November 2011 - Condition: Chronic Hepatitis C
Interventions: Drug: Peginterferon alfa-2a and Ribavirin; Drug: Peginterferon alfa-2a and Ribavirin
Sponsors: Pusan National University Yangsan Hospital; Pusan National University Yangsan Hospital; Severance Hospital; Pusan National University Hospital; Incheon St.Mary's Hospital; Soon Chun Hyang University Bucheon Hospital; Inje University; Inje University Ilsan Paik Hospital; Inje University Haeundae Paik Hospital
Recruiting - verified April 2012 - Condition: Hepatitis C
Interventions: Other: Ribavrin; Drug: Abacavir plus Ribavirin
Sponsors: Johns Hopkins University; Johns Hopkins University; GlaxoSmithKline; University of Nebraska
Recruiting - verified January 2010 - Conditions: Liver Transplantation; Hepatitis B; Liver Disease
Intervention: Drug: Entecavir
Sponsors: HepNet Study House, German Liverfoundation; HepNet Study House, German Liverfoundation; Hannover Medical School
Recruiting - verified April 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: COPEGUS
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Conditions: Chronic Hepatitis C; Oxidative Stress
Interventions: Dietary Supplement: silymarin; Dietary Supplement: green tea extract (EGCG)
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; National Center for Complementary and Alternative Medicine (NCCAM); National Institutes of Health (NIH)
Recruiting - verified November 2011 - Conditions: HIV Infections; Hepatitis C Virus
Intervention:
Sponsors: Rockefeller University; Rockefeller University
Recruiting - verified February 2012 - Conditions: HIV Infection; Liver Failure; Liver Transplantation
Intervention: Drug: Raltegravir potassium
Sponsors: French National Agency for Research on AIDS and Viral Hepatitis; French National Agency for Research on AIDS and Viral Hepatitis; Merck
Recruiting - verified December 2011 - Condition: Chronic Hepatitis C
Interventions: Drug: IFN alfa-2b XL 27 MUI + Ribavirin; Drug: IFN alfa-2b XL 36 MUI + Ribavirin; Drug: IFN peg alfa-2b 1.5 µg/kg + Ribavirin
Sponsors: French National Agency for Research on AIDS and Viral Hepatitis; French National Agency for Research on AIDS and Viral Hepatitis
Recruiting - verified February 2012 - Conditions: Hepatitis C; Alcohol Use Disorders
Interventions: Drug: baclofen; Drug: placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified January 2012 - Condition: Hepatitis C
Interventions: Drug: MK-5172; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Hepatitis C
Interventions: Drug: Midazolam; Drug: BMS-791325
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified February 2012 - Condition: Hepatitis B
Interventions: Drug: Simvastatin; Drug: Tenofovir; Drug: Entecavir
Sponsors: Bader, Ted, M.D.; Bader, Ted, M.D.
Recruiting - verified June 2011 - Conditions: Nevirapine Induced Rash; Nevirapine Induced Hepatitis; HIV; Adverse Side Effects; AIDS; HIV Infections
Interventions: Genetic: Genetic test for NVP induced rash; Other: 3TC/D4T/NVP or 3TC/AZT/NVP
Sponsors: Mahidol University; Mahidol University; Department of Medicine,Ramathibodi Hospital; Chulalongkorn University; Bamrasnaradura Institute, Ministry of Public Health; Thammasat University; Department of Preventive Medicine,Srinakharinwirot University; Chiang Rai Hospital; Maharaj Nakornratchasima Hospital; Department of Internal Medicine,Sawanpracharak Hospital; Department of Internal Medicine,Burirum Hospital; Department of Internal Medicine,Nakornping Hospital; National Institute of Health, Department of Medical Sciences; Clinical Research Center,Ministry of Public Health; RIKEN
Recruiting - verified July 2010 - Condition: Chronic Hepatitis B
Intervention: Drug: Peg-Interferon alfa 2a + Adefovir dipivoxil, Peg-Interferon alfa 2a + Tenofovir disoproxil fumarate
Sponsors: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Recruiting - verified September 2009 - Condition: Chronic Hepatitis B
Intervention:
Sponsors: Chang Gung Memorial Hospital; Chang Gung Memorial Hospital
Recruiting - verified March 2010 - Condition: Asymptomatic Chronic HCV Carriers
Intervention: Drug: Bovine Colostrum Powder
Sponsors: Hadassah Medical Organization; Hadassah Medical Organization
Not yet recruiting - verified June 2011 - Condition: Hepatitis C Virus
Interventions: Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified February 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: Vaniprevir (600 mg b.i.d.); Drug: Vaniprevir (300 mg b.i.d.); Drug: Pegylated interferon (Peg-IFN); Drug: Ribavirin (RBV)
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified July 2011 - Condition: Hepatitis B, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: Adefovir; Drug: Entecavir; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: Hepatitis B, Chronic
Intervention: Drug: peginterferon alfa-2a [Pegasys]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Conditions: Carcinoma, Hepatocellular; Liver Cirrhosis, Alcoholic; Hepatitis, Alcoholic; Hepatitis, Chronic; Hepatitis, Viral, Human
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Chronic Hepatitis B
Intervention: Drug: LDT600 (Telbivudine)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: HIV Infections; Hepatitis C
Interventions: Drug: Alcohol; Drug: Alcohol placebo
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified April 2012 - Condition: Rift Valley Fever
Intervention: Biological: Inactivated, Dried (TSI-GSD 200), RVF Vaccine
Sponsors: U.S. Army Medical Research and Materiel Command; U.S. Army Medical Research and Materiel Command
Recruiting - verified January 2012 - Condition: Chronic Hepatitis C
Interventions: Drug: Ribavirin; Drug: Colchicine
Sponsors: Hospital Universitario Ramon y Cajal; Hospital Universitario Ramon y Cajal
Recruiting - verified May 2012 - Conditions: Hepatitis C, Chronic; Cognition Disorders; Fatigue Syndrome, Chronic; Major Depressive Disorder
Interventions: Drug: Interferon and ribavirin; Drug: Interferon Alfa-2a + ribavirin
Sponsors: University of Aarhus; Aarhus University Hospital
Recruiting - verified December 2011 - Conditions: Acute Hepatitis A; Acute Hepatitis B; Acute Hepatitis C; Acute Hepatitis E; Acute EBV Hepatitis; Acute CMV Hepatitis
Interventions: Dietary Supplement: Silymarin; Dietary Supplement: Silymarin; Other: Lactose monohydrate
Sponsors: University of Maryland; University of Maryland; MADAUS GmbH; The Egyptian Company for Blood Transfusion Services (EgyBlood); Tanta Fever Hospital; Banha Fever Hospital; Alexandria University
Recruiting - verified August 2011 - Conditions: Poliomyelitis; Haemophilus Influenzae Type b Disease; Hepatitis B; Diphtheria; Pertussis; Tetanus
Intervention: Biological: Infanrix™ hexa
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified August 2011 - Condition: Chronic Hepatitis C
Interventions: Drug: Peginterferon; Drug: Ribavirin
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified October 2011 - Conditions: Hepatitis B; Liver Transplantation
Intervention: Biological: HepaGam B
Sponsors: Cangene Corporation; Cangene Corporation
Recruiting - verified April 2012 - Condition: Hepatitis C
Intervention: Behavioral: Integrated care model
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified January 2012 - Condition: Hepatitis C, Chronic
Interventions: Procedure: Liver Biopsy; Drug: Peginterferon & Ribavirin for Hepatitis C; Drug: Pre-treatment Ribavirin
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 2012 - Condition: Dengue Fever
Intervention: Genetic: CLEC5A
Sponsors: Kaohsiung Medical University Chung-Ho Memorial Hospital; Kaohsiung Medical University Chung-Ho Memorial Hospital; Centers for Disease Control and Prevention
Recruiting - verified December 2011 - Condition: Chronic Hepatitis C
Interventions: Drug: ribavirin; Drug: ribavirin
Sponsors: Foundation for Liver Research; Foundation for Liver Research; Hoffmann-La Roche
Recruiting - verified February 2012 - Conditions: Chronic Hepatitis C; Atherosclerosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2012 - Condition: Hepatitis C
Intervention:
Sponsors: University Hospital, Strasbourg, France; University Hospital, Strasbourg, France
Recruiting - verified August 2011 - Condition: Chronic Hepatitis C
Interventions: Drug: pegylated interferon alpha 2a and plus ribavirin; Drug: Pegylated interferon alfa-2a and ribavirin; Drug: pegylated interferon alpha 2a and ribavirin; Drug: pegylated interferon alpha 2a and ribavirin
Sponsors: Kaohsiung Medical University Chung-Ho Memorial Hospital; Kaohsiung Medical University Chung-Ho Memorial Hospital
Recruiting - verified April 2012 - Conditions: Chronic Hepatitis B e Antigen Positive; Chronic Hepatitis B e Antigen Negative
Intervention: Drug: Tenofovir/ & Emtricitabine
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified November 2011 - Condition: Chronic Hepatitis C
Interventions: Drug: Peg-interferon alpha 2a and ribavin; Drug: ribavirin with adaptation dose
Sponsors: Hospices Civils de Lyon; Hospices Civils de Lyon
Recruiting - verified January 2012 - Condition: Hepatitis C
Intervention: Drug: Ribavirin
Sponsors: Maastricht University Medical Center; Maastricht University Medical Center; Roche Pharma AG
Recruiting - verified July 2011 - Condition: Hepatitis C, Chronic
Intervention: Drug: peginterferon alfa-2a [Pegasys]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: HIV Infections
Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate; Drug: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Bill and Melinda Gates Foundation
Recruiting - verified May 2012 - Condition: Hepatitis C
Intervention:
Sponsors: Rockefeller University; Rockefeller University; New York Presbyterian Hospital
Recruiting - verified April 2012 - Condition: Hepatitis B, Chronic
Intervention: Drug: Entecavir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified October 2011 - Conditions: Iron Overload; Metabolic Syndrome X; Hepatitis B; Hepatitis C; Alcohol Abuse
Intervention: Device: Magnetic resonance imaging multiecho gradient-echo sequence
Sponsors: Rennes University Hospital; Rennes University Hospital; Ministry of Health, France
Recruiting - verified February 2012 - Condition: Hepatitis C Virus Infection
Interventions: Drug: Interferon injections and ribavirin; Drug: Interferon injections and ribavirin
Sponsors: University of British Columbia; University of British Columbia; Canadian Institutes of Health Research (CIHR)
Recruiting - verified November 2011 - Conditions: Biliary Liver Cirrhosis,; Hemochromatosis; Hepatitis; Hepatolenticular Degeneration; Liver Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified December 2011 - Condition: Liver Fibrosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2011 - Condition: Hepatitis C Virus
Intervention:
Sponsors: Rockefeller University; Rockefeller University; National Institute of Allergy and Infectious Diseases (NIAID); New York Presbyterian Hospital
Recruiting - verified May 2012 - Conditions: Birth Defects; Pregnancy Complications; Hepatitis C
Intervention:
Sponsors: INC Research; INC Research; Aurobindo; Genentech; Sandoz Inc.; Merck; Teva Pharmaceuticals USA; Kadmon Pharmaceuticals, LLC; Zydus Pharmaceuticals USA, Inc.
Recruiting - verified October 2011 - Conditions: Hepatitis C; HIV Infections
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012 - Condition: Virus Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC)
Recruiting - verified May 2012 - Condition: Hepatitis C
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified November 2011 - Condition: Hepatitis C
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC)
Recruiting - verified January 2012


